Johnson & Johnson stock edges higher as Apollo deal talks and guidance boost draw attention

Published on 09/14/2026 at 14:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Johnson & Johnson stock trades near a 12?month high after the company raised its 2026 sales and EPS guidance in its latest quarterly update. Investors are also watching reported talks to sell its orthopedics unit to Apollo in a deal worth close to USD 20 billion.

Johnson & Johnson, US4781601046, Illustration mit AI erstellt.

Johnson & Johnson stock (ISIN US4781601046) is trading close to its recent highs, with the share at USD 266.20 on the New York Stock Exchange as of September 13, 2026, valuing the healthcare group at about USD 640.1 billion. As highlighted by Zacks Investment Ideas on September 14, 2026, strong operational performance has allowed Johnson & Johnson to lift its current fiscal-year sales and adjusted EPS guidance, putting the company on track to exceed USD 100 billion in annual revenue for 2026 for the first time in its history.

Guidance raised and revenue growth supports valuation

According to MarketBeat on September 14, 2026, Johnson & Johnson reported quarterly earnings per share of USD 2.90 and revenue of USD 25.31 billion in its most recent quarter, with the quarter ending in 2026, representing revenue growth of 6.6% compared with the same quarter a year earlier. The same source notes that management reaffirmed its full-year 2026 adjusted EPS guidance in a range of USD 11.60 to USD 11.75, underscoring confidence in the earnings trajectory and giving investors a concrete framework to compare the current valuation against expected profits.

The combination of a 6.6% year-over-year revenue increase to USD 25.31 billion and guidance for 2026 EPS around USD 11.60 to USD 11.75 means Johnson & Johnson is targeting both top-line expansion and margin stability within the current fiscal year. For investors, the perspective that annual revenue could surpass USD 100 billion in 2026, as emphasized by Zacks Investment Ideas, offers a clear quantitative milestone that supports the company’s premium valuation in the healthcare sector.

Apollo deal talks highlight portfolio reshaping

Beyond earnings, attention has turned to portfolio strategy after reports that Johnson & Johnson is in discussions to sell its orthopedics unit. As Economic Times reported on September 14, 2026, Apollo Global Management is in talks to acquire Johnson & Johnson’s orthopedics division in a transaction that could value the business at close to USD 20 billion. Such a potential divestment would further streamline Johnson & Johnson’s portfolio toward higher-growth and higher-margin segments while releasing substantial capital that could be redeployed into research and development, acquisitions or shareholder returns.

For shareholders, the reported USD 20 billion deal value can be compared with Johnson & Johnson’s current market capitalization of about USD 640.1 billion as of September 13, 2026, suggesting that the orthopedics unit accounts for a mid-single-digit percentage of the group’s total equity value. If completed near the indicated valuation, the transaction would underscore the value embedded in non-core assets and could serve as a catalyst for re-rating if investors conclude that the company’s remaining businesses deserve a higher earnings multiple than the conglomerate structure has historically commanded.

Analyst targets and product approvals frame upside and risks

According to news cited on the Johnson & Johnson stock overview at Robinhood on September 14, 2026, HSBC has raised its price target for Johnson & Johnson shares to USD 320 from USD 290 while maintaining a Buy rating, reflecting increased confidence in the company’s growth and cash-flow profile. The new target implies upside of roughly USD 53.80 per share from the recent price of USD 266.20 on the primary listing, highlighting that at least some analysts see room for further gains despite the stock trading close to its 12-month highs.

From a broader consensus perspective, MarketBeat reports that Johnson & Johnson carries a Moderate Buy consensus rating, with an average analyst price target of USD 274.13 compared with the current share price in the mid-260s. The same overview notes that one analyst rates the stock a Strong Buy, 18 rate it a Buy and six assign a Hold rating, indicating that while sentiment is broadly constructive, valuation and recent share-price strength have led some houses to adopt a more cautious stance.

Product news is also contributing to the investment case. As noted by Business Wire on September 10, 2026, Johnson & Johnson has received CE Marking in Europe for its ACUVUE OASYS MAX 2-Week reusable contact lenses, with a phased rollout planned from late 2026 and broader market expansion through 2027 and 2028. In addition, MarketBeat highlights that China has approved Icotyde, the company’s once-daily oral treatment for moderate-to-severe plaque psoriasis, opening access to a large patient population and reinforcing the pipeline-driven growth narrative.

Stock trades near recent highs with solid volume

On the market side, data from a Johnson & Johnson stock quote page accessed on September 14, 2026 show that the shares traded at USD 266.20 on the primary U.S. exchange during the session on September 13, 2026, after reaching an intraday high of USD 270.39 and a low of USD 265.25, with trading volume of about 4.71 million shares and an average volume of 6.17 million. With this price level, the stock stands modestly below its recent daily high while remaining above the session low, giving investors an entry point that is slightly off the upper end of the recent trading range.

Additional data from another stock portal indicate that the Johnson & Johnson share recently closed at USD 265.58, with a 12-month high of around USD 270.40 and a 12-month low significantly below the current price, meaning the stock is trading within roughly USD 4.82 of its recent peak. For long-term holders, the combination of a market capitalization of approximately USD 640.1 billion as of September 13, 2026, steadily rising revenue and EPS guidance and a pipeline of new products and potential portfolio reshaping transactions suggests that the key questions now revolve around whether earnings can grow fast enough to justify the current valuation multiple and how proceeds from any asset sales will be deployed.